Healthspan Capital is an early-stage longevity venture capital firm that invests in biotechnology startups developing therapies to slow or reverse aging.
Investment Type: Venture Capital
Investment Stage: Pre-Seed; Seed; Series A
Portfolio 19
| Date | Name | Website | Total Raised | Location |
| 30.06.2025 | Immunis Bi... | immunisbiomedical.com | - | United Sta... |
| 30.06.2025 | etherospharma.com | - | - | |
| - | oldenlabs.com | - | - | |
| - | Shift Bios... | shiftbioscience.com | $16.33M | United Kin... |
| - | Vincere Bi... | vincerebio.com | - | United Sta... |
| - | Resevoir N... | reservoirneuro.com | $4M | United Sta... |
| - | Oisín Biot... | oisinbio.com | $15M | - |
| - | Weatherwax... | weatherwax.bio | - | United Sta... |
| - | 302 Found | zoebiosciences.com | - | - |
| - | Samsara Th... | samsaratherapeutics.com | $3.2M | United Kin... |
Show more
Mentions in press and media 4
| Date | Title | Description |
| 13.10.2022 | KetoSwiss secures $4 million | |
| 13.10.2022 | KetoSwiss secures $4 million pre-seed capital | |
| 18.08.2022 | 5 investors explain why longevity tech is a long-term play | Of all the stories passed on through history, the tales of life unending have persisted in the human imagination without much change. The details differ, but nearly every civilization right from the time of the Egyptians has in some form or... |
| 18.08.2022 | These 5 investors are betting on helping you live longer and better | Analysts estimate that the market for “delaying human death” could be worth $610 billion by 2025. But that doesn’t sit well with Christian Angermayer, who co-founded Cambrian BioPharma and Rejuveneron, and whose family office Apeiron Invest... |